Results 31 to 40 of about 21,696 (215)

Ruxolitinib: A restorative of COVID-19

, 2022
Despite mass level vaccinations and the launch of several repurposed drugs, the recently emerged SARS CoV-2 Omicron (B.1.1.529) is a variant of concern. New drugs must be discovered with artificial intelligence (AI) assistance.
Kamal Rawal, Preeti P, Trapti Sharma, Robin Sinha, Surabhi Gangani   +4 more
core   +1 more source

Recent progress of JAK inhibitors for hematological disorders

Immunological Medicine, 2023
JAK inhibitors are important therapeutic options for hematological disorders, especially myeloproliferative neoplasms. Ruxolitinib, the first JAK inhibitor approved for clinical use, improves splenomegaly and ameliorates constitutional symptoms in both ...
Keita Kirito
doaj   +1 more source

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis

Hematology, 2022
Objectives Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the ...
Timothy Devos, Dominik Selleslag, Nikki Granacher, Violaine Havelange, Fleur Samantha Benghiat   +4 more
doaj   +1 more source

Potential Benefit of Ruxolitinib in Suspected Ocular and Neurological Transplant-Associated Thrombotic Microangiopathy After Allogeneic Stem Cell Transplantation: A Case Report and Review. [PDF]

Clin Case Rep
ABSTRACT We describe a rare case of suspected delayed‐onset TA‐TMA with ocular and neurological involvement following allo‐HSCT. The condition was refractory to standard therapies; neurological improvement was temporally associated with ruxolitinib initiation, suggesting a possible GVHD overlap.
Pillet LM, Arandilla A, Sauvetre G, Goupillou P, Lefevre A, Grall M, Bonnevalle A, Bourre B, Penther D, Porcheron S, Jardin F, Alani M, Dubois S, Camus V.   +13 more
europepmc   +2 more sources

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Journal of Hematology & Oncology, 2017
Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor,
Srdan Verstovsek, Jason Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, Claire N. Harrison, Ronald Paquette, William Sun, Ahmad Naim, Peter Langmuir, Tuochuan Dong, Prashanth Gopalakrishna, Vikas Gupta   +13 more
doaj   +1 more source

Trends in overall mortality among US veterans with primary myelofibrosis

BMC Cancer, 2023
Background Primary myelofibrosis [PMF] is a myeloproliferative neoplasm associated with reduced overall survival (OS). Management strategies for PMF have evolved over the last two decades, including approval of ruxolitinib as the first Janus kinase 1 ...
Tsewang Tashi, Jingbo Yu, Shivani Pandya, Christopher Dieyi, Robyn Scherber, Shreekant Parasuraman   +5 more
doaj   +1 more source

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

, 2022
Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, typically associated with disease-related symptoms, splenomegaly, cytopenias and bone marrow fibrosis. Patients experience a significant symptom burden and a reduced life expectancy.
Gerds, Aaron T., Verstovsek, Srdan, Alvarez-Larrán, Alberto, Grosicki, Sebastian, Colak, Gozde, Kremyanskaya, Marina, Palandri, Francesca, Patriarca, Andrea, Harrison, Claire N., Mascarenhas, John, Kuykendall, Andrew T., Kiladjian, Jean-Jacques, Mead, Adam J., Gupta, Vikas K., Al-Ali, Haifa Kathrin, Mesa, Ruben, Rampal, Raajit, Talpaz, Moshe, Sheikine, Yuri, Devos, Timothy, Buxhofer-Ausch, Veronika, Akhani, Sanjay, Wondergem, Marielle J., Vannucchi, Alessandro M., Jourdan, Eric   +24 more
core   +1 more source

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Journal of Hematology & Oncology, 2017
Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark Jones, Deanna Kornacki, Kang Sun, Hagop Kantarjian, for the COMFORT-I investigators   +21 more
doaj   +1 more source

Ruxolitinib in Patients With Chronic Active Epstein-Barr Virus Infection: A Retrospective, Single-Center Study

Frontiers in Pharmacology, 2021
Background: Chronic active Epstein-Barr virus (CAEBV) infection is one of the EBV-positive T- or NK-cell lymphoproliferative diseases. There is no safe and effective treatment currently and the only proven curable therapy is allogeneic hematopoietic stem
Yue Song, Jingshi Wang, Yini Wang, Zhao Wang   +3 more
doaj   +1 more source

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Cancer Medicine, 2019
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease‐related symptoms in patients with myelofibrosis (MF).
Novella Pugliese, Claudia Giordano, Davide Nappi, Luigiana Luciano, Claudio Cerchione, Mario Annunziata, Beniamino Casale, Elena Crisà, Maria Rosaria Villa, Luca Pezzullo, Maria Iovine, Marco Picardi, Francesco Grimaldi, Fabrizio Pane, Vincenzo Martinelli   +14 more
doaj   +1 more source